633314-22-4

Basic information

• Product Name: Carbonic acid, 2,6-bis[[[(1,1-dimethylethyl)dimethylsilyl]oxy]methyl]-4-methylphenyl 4-nitrophenyl ester
• CAS NO: 633314-22-4
• Molecular Formula: C28H43NO7Si2
• Molecular Weight: 561.823
• Mol File: 633314-22-4.mol

Chemical Properties

• CAS DataBase Reference: Carbonic acid, 2,6-bis[[[(1,1-dimethylethyl)dimethylsilyl]oxy]methyl]-4-methylphenyl 4-nitrophenyl ester(CAS DataBase Reference)
• NIST Chemistry Reference: Carbonic acid, 2,6-bis[[[(1,1-dimethylethyl)dimethylsilyl]oxy]methyl]-4-methylphenyl 4-nitrophenyl ester(633314-22-4)
• EPA Substance Registry System: Carbonic acid, 2,6-bis[[[(1,1-dimethylethyl)dimethylsilyl]oxy]methyl]-4-methylphenyl 4-nitrophenyl ester(633314-22-4)

Safety Data

• Hazardous Substances Data: 633314-22-4(Hazardous Substances Data)

Upstream product

• 122-04-3 4-nitro-benzoyl chloride 
• 633314-21-3 2,6-bis(((tert-butyldimethylsilyl)oxy)methyl)-4-methylphenol 
• 18162-48-6 tert-butyldimethylsilyl chloride 
• 91-04-3 2,6-bis(hydroxymethyl)-4-methylphenol 
• 7693-46-1 4-Nitrophenyl chloroformate 

Downstream Products

• 1338829-40-5 C₃₉H₅₉BrN₂O₁₀Si₂ 
• 1277190-55-2 C₂₇H₃₁BrN₂O₁₀ 
• 1338829-41-6 C₂₅H₂₇BrN₂O₉ 
• 1236141-71-1 C₃₆H₅₉N₃O₁₀Si₂ 
• 673485-37-5 C₅₁H₆₀N₆O₂₂ 
• 673485-36-4 [2-({4-[({2-[(2,6-bis-hydroxymethyl-4-methyl-phenoxycarbonyl)-methyl-amino]-ethyl}-methyl-carbamoyloxy)-methyl]-2,6-dimethoxy-phenoxycarbonyl}-methyl-amino)-ethyl]-methyl-carbamic acid 3-hydroxy-3-methyl-5-oxo-hexyl ester 
• 633314-25-7 C₃₃H₃₆N₄O₁₄ 
• 633314-24-6 {2-[(2,6-bis-hydroxymethyl-4-methyl-phenoxycarbonyl)-methyl-amino]-ethyl}-methyl-carbamic acid tert-butyl ester 

Relevant articles and documents

Antibiotic modified anticancer compounds for the treatment of non-genetic anti-cancer and anticancer pharmaceutical composition comprising the same

The present invention relates to an antibiotic modified anti-cancer compound for gene non-toxic anticancer therapy and an anticancer pharmaceutical composition comprising the same. A method for treating mitochondria target using a compound according to th

Mitochondrial Relocation of a Common Synthetic Antibiotic: A Non-genotoxic Approach to Cancer Therapy

Tumor recurrence as a result of therapy-induced nuclear DNA lesions is a major issue in cancer treatment. Currently, only a few examples of potentially non-genotoxic drugs have been reported. Mitochondrial re-localization of ciprofloxacin, one of the most

Photo-thermal assistant penetration diagnosis and treatment type nanometer medicine (by machine translation)

The invention belongs to the technical field of biology, and particularly relates to a diagnosis and treatment drug for assisting in deep penetration of tumors by utilizing a photo-thermal effect. The in-situ released probe, under near-infrared illuminati

Selenium-containing paclitaxel dimer prodrug polymer nanoparticle and preparation method thereof

The invention belongs to the field of pharmaceutical preparations, and relates to a selenium-containing paclitaxel dimer prodrug polymer nanoparticle and a preparation method thereof. The preparationis a selenium-containing paclitaxel dimer prodrug polymer nano-drug delivery system prepared from a selenium-containing paclitaxel dimer prodrug, a polyethylene glycol-polypolyphenylalanine amphiphilic polymer material, a polypeptide-modified polyethylene glycol-polyphenylalanine amphiphilic polymer material, and the like; the selenium-containing paclitaxel dimer prodrug polymer nano drug deliverysystem. The selenium-containing paclitaxel dimer prodrug is synthesized and encapsulated in the polyethylene glycol-polyphenylalanine amphiphilic polymer materials, by virtue of a special dimer structure, the high-drug-loading polymer nanoparticle0 is prepared, a Se-Se bond is introduced in the synthesis of the dimer prodrug, carrier stability can be effectively improved, and the controllable release of the drug in target cells can be realized; by modification of polypeptide molecules, the breast cancer targeting property of the nanoparticle can be obviously improved, the accumulation of thedrug is improved, and the anti-tumor effect of the drug is improved.

A self-immolative and DT-diaphorase-activatable prodrug for drug-release tracking and therapy

DT-diaphorase, which catalyzes the reduction of various biological substances like quinones, is overexpressed in some malignant tumors. However, exploiting this attractive property for the controlled release of an active drug from a prodrug is yet to be fully taken advantage of. Herein we report a DT-diaphorase-based prodrug for concomitant drug-release imaging and cancer chemotherapy. This prodrug system is composed of two camptothecin (CPT) moieties as the active anticancer drug, a DT-diaphorase-responsive quinone propionic acid moiety and a set of self-immolative linkers. The presence of DT-diaphorase leads to the release of two CPT molecules and restores the fluorescence of the latter, thereby realizing the fluorescence monitoring of the DT-diaphorase level as well as the tracking of CPT release. Upon internalization by DT-diaphorase overexpressing cells, the prodrug can release fluorescent CPT and exhibit high cytotoxicity (half-maximal inhibitory concentration 0.71 μM) towards the cancer cells. This prodrug features on-demand enzyme-biomarker-triggered drug release as well as self-monitoring of drug release, therapeutic effect and biomarker level. This new strategy may provide an effective approach for constructing prodrugs with enhanced drug loading as well as controllability for drug release and tracking.

Low power, biologically benign NIR light triggers polymer disassembly

Near infrared (NIR) irradiation can penetrate up to 10 cm deep into tissues and be remotely applied with high spatial and temporal precision. Despite its potential for various medical and biological applications, there is a dearth of biomaterials that are responsive at this wavelength region. Herein we report a polymeric material that is able to disassemble in response to biologically benign levels of NIR irradiation upon two-photon absorption. The design relies on the photolysis of the multiple pendant 4-bromo7-hydroxycoumarin protecting groups to trigger a cascade of cyclization and rearrangement reactions leading to the degradation of the polymer backbone. The new material undergoes a 50% Mw loss after 25 s of ultraviolet (UV) irradiation by single photon absorption and 21 min of NIR irradiation via two-photon absorption. Most importantly, even NIR irradiation at a biologically benign laser power is sufficient to cause significant polymer disassembly. Furthermore, this material is well tolerated by cells both before and after degradation. These results demonstrate for the first time a NIR sensitive material with potential to be used for in vivo applications.

UV and near-IR triggered release from polymeric nanoparticles

A new light-sensitive polymer containing multiple light-sensitive triggering groups along the backbone and incorporating a quinone-methide self-immolative moiety was developed and formulated into nanoparticles encapsulating a model pharmaceutical Nile Red. Triggered burst release of the payload upon irradiation and subsequent degradation of the nanoparticles were observed. This system is designed to be versatile where the triggering group can be sensitive to a number of wavelengths.

Bioactivation of Self-Immolative Dendritic Prodrugs by Catalytic Antibody 38C2

Self-immolative dendrimers have recently been developed and introduced as a potential platform for a multi-prodrug. These unique structural dendrimers can release all of their tail units, through a self-immolative chain fragmentation, which is initiated b